Arvinas to Present at the UBS Global Healthcare Virtual Conference

Rhea-AI Summary

Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, has announced that John Houston and Ian Taylor will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 10:00 a.m. ET. The event will be available via a live audio webcast and archived for 30 days on Arvinas' website. Arvinas aims to improve patient lives by developing therapies that degrade disease-causing proteins, with two clinical-stage programs: ARV-110 for prostate cancer and ARV-471 for breast cancer.

News Market Reaction – ARVN

+3.99%

+3.99% Session move

In the trading session that priced this news, ARVN gained 3.99%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 10:00 a.m. ET.

A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.

About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC^® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC^® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC^® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

Investors
Will O’Connor, Stern Investor Relations
ir@arvinas.com

Media
Kirsten Owens, Arvinas Communications
kirsten.owens@arvinas.com 

FAQ

What is the date and time of the Arvinas fireside chat?

The Arvinas fireside chat will take place on May 25, 2021, at 10:00 a.m. ET.

Where can I listen to the Arvinas presentation?

The presentation can be accessed through a live audio webcast available on Arvinas' website.

What are the clinical-stage programs of Arvinas?

Arvinas has two clinical-stage programs: ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for locally advanced or metastatic ER+/HER2- breast cancer.

What is the focus of Arvinas as a biotechnology company?

Arvinas focuses on creating therapies that degrade disease-causing proteins using its PROTAC® Discovery Engine platform.

How long will the Arvinas webcast be available after the event?

The webcast will be archived on Arvinas' website for 30 days following the presentation.